ATC Group: C09BB ACE inhibitors and calcium channel blockers

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C09BB in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C09 Agents acting on the renin-angiotensin system
3 C09B ACE inhibitors, combinations
4 C09BB ACE inhibitors and calcium channel blockers

Group C09BB contents

Code Title
C09BB02 Enalapril and lercanidipine
C09BB03 Lisinopril and amlodipine
C09BB04 Perindopril and amlodipine
C09BB05 Ramipril and felodipine
C09BB06 Enalapril and nitrendipine
C09BB07 Ramipril and amlodipine
C09BB10 Trandolapril and verapamil
C09BB12 Delapril and manidipine

Active ingredients in C09BB

Active Ingredient Description
Delapril and Manidipine

Fixed dose combination of delapril, an inhibitor of the angiotensin conversion enzyme, and manidipine, a dyhydropyridine calcium-antagonist with antihypertensive activity and nephroprotecting properties. The combination of these active ingredients through complementary mechanisms of action produces a synergistic antihypertensive effect, reducing blood pressure in a greater measure than with the single constituents.

Enalapril and Lercanidipine

Fixed combination of an ACE-inhibitor, enalapril, and a calcium channel blocker, lercanidipine, two antihypertensive compounds with complementary mechanism of action to control blood pressure in patients with essential hypertension. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.

Enalapril and Nitrendipine

The two active substances have a complementary antihypertensive effect. Once absorbed, enalapril is hydrolyzed to enalaprilat, a substance that inhibits ACE. This inhibition results in a decrease in plasma angiotensin II, which leads to an increase in plasma renin activity and a decrease in aldosterone secretion. Enalapril has an antihypertensive effect even in cases of hypertension with low renin. Nitrendipine is a calcium antagonist of the 1-4 dihydropyridine group that acts as an antihypertensive agent. The mechanism of action of nitrendipine is based on the inhibition of the flow of calcium ions in the smooth muscle fibers of the vessels.

Lisinopril and Amlodipine
Perindopril and Amlodipine

Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). Perindopril is active in all grades of hypertension: mild, moderate, severe; a reduction in systolic and diastolic blood pressures in both supine and standing positions is observed. Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle.

Ramipril and Amlodipine

Ramiprilat, the active metabolite of the prodrug ramipril, catalyses the conversion of angiotensin I to the active vasoconstrictor substance angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation. Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements. The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions.

Ramipril and Felodipine

Both the calcium antagonist felodipine and the ACE inhibitor ramipril reduce blood pressure by dilation of the peripheral blood vessels. Calcium antagonists dilate the arterial beds while ACE inhibitors dilate both arterial and venous beds. Vasodilatation and thereby reduction of blood pressure may lead to activation of the sympathetic nervous system and the renin-angiotensin system. Inhibition of ACE results in decreased plasma angiotensin II.

Related product monographs

Title Information Source Document Type  
COVERAM Tablet Medicines Authority (MT) MPI, EU: SmPC
COVERAM Tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
LERCARIL 10 mg/10 mg Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
LERCARIL 20 mg/10 mg Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
LERCARIL 20 mg/20 mg Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
PRESTALIA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
REAPTAN Tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
TRIAPIN Prolonged release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC